Welcome to RITUXAN
RITUXAN® (rituximab) is a prescription medicine used to treat Non-Hodgkin’s Lymphoma (NHL)
RITUXAN® (rituximab) is a prescription medicine used to treat Non-Hodgkin’s Lymphoma (NHL)
Model on website does not depict actual patient.
*Eligibility criteria and annual limits apply. Not valid for patients using federal or state government programs to pay for their medications. Patients must be taking RITUXAN for an FDA-approved indication. See full TERMS AND CONDITIONS.
RITUXAN is available by prescription only.
Non-Hodgkin’s Lymphoma (NHL) is a type of blood cancer that affects lymphocytes, which are part of the immune system. When untreated, NHL can worsen and impact a patient's health and well-being. Rituxan® (rituximab) is an FDA-approved treatment for adults with certain types of NHL, including diffuse large b-cell lymphoma (DLBCL) and follicular lymphoma. Learn more about how Rituxan works.
Rituxan is administered via intravenous infusion under the guidance of your healthcare provider. Prior to your first infusion, you may need to prepare by consulting your healthcare provider. Rituxan dosing schedules vary by patient needs, and your healthcare provider will determine the right approach for you.
Potential side effects of Rituxan include infusion-related reactions, such as fever, chills, or nausea, and low blood cell counts. Speak with your healthcare provider to understand the goals of treatment and decide if Rituxan is right for you. Find helpful resources and tips to work with your care team and manage your NHL treatment effectively.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.